InflaRx reports Q2 EPS (21c) vs. (24c) last year

Reports revenue EUR 39,432 vs. EUR 6,357 last year. Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx (IFRX), commented: “With the development of INF904, an oral C5aR inhibitor with best-in-class potential, InflaRx remains committed to targeting unmet needs in inflammatory disease and bringing new hope to patients. Data informing the clinical utility of INF904 in chronic spontaneous urticaria and hidradenitis suppurativa are anticipated in the fall, potentially unlocking significant value in this pipeline program and driving INF904 one step further as an effective and safe oral option for patients with these painful and debilitating skin conditions.”